60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
60 Degrees Pharmaceuticals (NASDAQ: SXTP), a pharmaceutical company focused on vector-borne disease treatments, has announced an updated schedule for their presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will now take place on Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel.
CEO Dr. Geoff Dow will deliver a live presentation, and the management team will be available for one-on-one meetings during the conference. The presentation will be accessible via webcast for interested investors.
60 Degrees Pharmaceuticals (NASDAQ: SXTP), azienda farmaceutica specializzata in terapie per malattie trasmesse da vettori, ha comunicato una modifica al calendario della propria presentazione al H.C. Wainwright 27th Annual Global Investment Conference. L'intervento si terrà ora martedì 9 settembre 2025 alle 15:30 ET presso il Lotte New York Palace Hotel.
Il CEO Dr. Geoff Dow terrà la presentazione in diretta e il management sarà disponibile per incontri one-to-one durante la conferenza. La presentazione sarà inoltre fruibile via webcast per gli investitori interessati.
60 Degrees Pharmaceuticals (NASDAQ: SXTP), una compañía farmacéutica centrada en tratamientos para enfermedades transmitidas por vectores, ha anunciado un cambio en el horario de su presentación en la H.C. Wainwright 27th Annual Global Investment Conference. La presentación se celebrará ahora el martes 9 de septiembre de 2025 a las 3:30 PM ET en el Lotte New York Palace Hotel.
El CEO Dr. Geoff Dow ofrecerá una presentación en vivo y el equipo directivo estará disponible para reuniones individuales durante la conferencia. La presentación también podrá seguirse por webcast para los inversores interesados.
60 Degrees Pharmaceuticals (NASDAQ: SXTP))는 매개체 감염 질환 치료제에 주력하는 제약사로, H.C. Wainwright 27th Annual Global Investment Conference에서의 발표 일정이 변경되었음을 발표했습니다. 발표는 2025년 9월 9일 화요일 동부시간(ET) 오후 3시 30분에 Lotte New York Palace Hotel에서 진행됩니다.
CEO Dr. Geoff Dow가 라이브로 발표하며 경영진은 컨퍼런스 기간 중 일대일 미팅이 가능합니다. 관심 있는 투자자들은 웹캐스트를 통해 발표를 시청할 수 있습니다.
60 Degrees Pharmaceuticals (NASDAQ: SXTP), société pharmaceutique spécialisée dans les traitements des maladies vectorielles, a annoncé une nouvelle date pour sa présentation lors de la H.C. Wainwright 27th Annual Global Investment Conference. La présentation aura désormais lieu le mardi 9 septembre 2025 à 15h30 ET à l'hôtel Lotte New York Palace.
Le CEO Dr. Geoff Dow fera une présentation en direct et l'équipe de direction sera disponible pour des rendez‑vous individuels pendant la conférence. La présentation sera également accessible en webcast pour les investisseurs intéressés.
60 Degrees Pharmaceuticals (NASDAQ: SXTP), ein Pharmaunternehmen, das sich auf Therapien für durch Vektoren übertragene Krankheiten spezialisiert hat, hat eine Aktualisierung des Zeitplans für seinen Auftritt auf der H.C. Wainwright 27th Annual Global Investment Conference bekanntgegeben. Die Präsentation findet nun am Dienstag, dem 9. September 2025, um 15:30 Uhr ET im Lotte New York Palace Hotel statt.
CEO Dr. Geoff Dow wird live präsentieren, und das Managementteam steht während der Konferenz für Einzelgespräche zur Verfügung. Interessierte Investoren können die Präsentation per Webcast verfolgen.
- None.
- None.
WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time.
Dr. Geoff Dow, 60 Degrees Pharma CEO, will present live and management will conduct one-on-one meetings during the conference.
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 9, 2025
Time: 3:30 PM ET
Location: Lotte New York Palace Hotel
Webcast: Register
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.
The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.
Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330
Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
FAQ
When is 60 Degrees Pharmaceuticals (SXTP) presenting at the H.C. Wainwright Conference?
Who will be presenting for 60 Degrees Pharmaceuticals (SXTP) at the H.C. Wainwright Conference?
What type of meetings will 60 Degrees Pharmaceuticals (SXTP) management conduct at the conference?
What is 60 Degrees Pharmaceuticals' (SXTP) main business focus?
